Skip to content

house · Committee report

H. Rept. 118-952

ENSURING PATIENT ACCESS TO CRITICAL BREAKTHROUGH PRODUCTS ACT OF 2024

2024-12-24

Committees

Associated legislation

Text

Dissenting Views

[To accompany H.R. 1691] [Including cost estimate of the Congressional Budget Office] The Committee on Ways and Means, to whom was referred the bill (H.R. 1691) to amend title XVIII of the Social Security Act to ensure prompt coverage of breakthrough devices under the Medicare program, and for other purposes, having considered the same, reports favorably thereon with an amendment and recommends that the bill as amended do pass. CONTENTS Page I. SUMMARY AND BACKGROUND...........................................3 A. Purpose and Summary................................. 3 B. Background and Need for Legislation................. 3 C. Legislative History................................. 4 Background......................................... 4 Committee Hearings................................. 4 Committee Action................................... 4 D. Designated Hearing.................................. 4 II. EXPLANATION OF THE BILL..........................................4 A. Reasons for Change.................................. 4 B. Explanation of Provisions........................... 5 C. Effective Date...................................... 5 III. VOTES OF THE COMMITTEE...........................................5 IV. BUDGET EFFECTS OF THE BILL.......................................6 A. Committee Estimate of Budgetary Effects............. 6 B. Statement Regarding New Budget Authority and Tax Expenditures Budget Authority...................... 6 C. Cost Estimate Prepared by the Congressional Budget Office............................................. 6 V. OTHER MATTERS TO BE DISCUSSED UNDER THE RULES OF THE HOUSE.......8 A. Committee Oversight Findings and Recommendations.... 8 B. Statement of General Performance Goals and Objectives......................................... 8 C. Information Relating to Unfunded Mandates........... 8 D. Congressional Earmarks, Limited Tax Benefits, and Limited Tariff Benefits............................ 9 E. Duplication of Federal Programs..................... 9 VI. CHANGES IN EXISTING LAW MADE BY THE BILL, AS REPORTED............9 VII. DISSENTING VIEWS...............................................102 The amendment is as follows: Strike all after the enacting clause and insert the following: SECTION 1. SHORT TITLE. This Act may be cited as the ``Ensuring Patient Access to Critical Breakthrough Products Act of 2024''. SEC. 2. ENSURING PROMPT COVERAGE OF BREAKTHROUGH DEVICES UNDER THE MEDICARE PROGRAM. (a) Ensuring Coverage Through a Transitional Coverage Period.-- (1) In general.--Section 1862(a)(1) of the Social Security Act (42 U.S.C. 1395y(a)(1)) is amended-- (A) in subparagraph (O), by striking ``and'' at the end; (B) in subparagraph (P), by adding ``and'' at the end; and (C) by inserting after subparagraph (P) the following new subparagraph: ``(Q) in the case of a breakthrough device (as defined in section 1861(nnn)) furnished during the transitional coverage period (as so defined) with respect to such device, which is not furnished in accordance with the Food and Drug Administration-approved labeling for such device or that the Secretary determines, based on a review of clinical data, presents an undue risk of harm that outweighs the potential clinical benefits for individuals entitled to benefits under part A or enrolled under part B;''. (2) Definitions.--Section 1861 of the Social Security Act (42 U.S.C. 1395x) is amended by adding at the end the following new subsection: ``(nnn) Breakthrough Device.-- ``(1) In general.--The term `breakthrough device' means a device so designated by the Secretary under section 1899C. ``(2) Transitional coverage period.--The term `transitional coverage period' means, with respect to a breakthrough device, the 4-year period that begins on the date that such device is so designated by the Secretary under section 1899C.''. (3) Breakthrough device determinations.--Part E of title XVIII of the Social Security Act (42 U.S.C. 1395x et seq.) is amended by adding at the end the following new section: ``SEC. 1899C. DESIGNATION OF BREAKTHROUGH DEVICES. ``(a) In General.--Beginning 18 months after the date of the enactment of this section, upon application of a manufacturer of a device (as defined in section 201 of the Federal Food, Drug, and Cosmetic Act) that is cleared, classified, or approved under section 510(k), 513(f)(2), or 515 of such Act on or after the date of the enactment of this section, the Secretary shall designate such device as a breakthrough device if the Secretary determines that such device meets the criteria specified in subsection (b). ``(b) Criteria.--For purposes of subsection (a), the criteria specified in this subsection are, with respect to a device, the following: ``(1) The device is provided with priority review pursuant to section 515B of the Federal Food, Drug, and Cosmetic Act. ``(2) In the case such device is cleared under section 510(k) of such Act, such device is so cleared based on clinical trial information from an applicable device clinical trial (as such terms are defined in section 402(j) of such Act) that enrolled individuals entitled to benefits under part A or enrolled under part B. ``(3) The device is not a clinical diagnostic laboratory test. ``(c) Determination Process.-- ``(1) In general.--The Secretary shall make a determination with respect to a device that is the subject of an application described in subsection (a) not later than 6 months after such application is submitted to the Secretary. ``(2) Explanation required in case of determination that device does not meet criteria for designation.--In the case that the Secretary determines that a device that is the subject of an application described in subsection (a) does not meet the criteria specified in subsection (b), the Secretary shall notify the manufacturer of such device of such determination and include in such notification an explanation identifying the specific criterion or criteria that such device failed to meet. ``(d) Reports.--The Secretary shall submit to Congress on an annual basis a report specifying-- ``(1) the number of applications received under this section during such year; ``(2) the number of devices designated as breakthrough devices under this section during such year; and ``(3) the number of applications for a designation for a device under this section with respect to which the Secretary determined that such device did not meet the criteria specified in subsection (b) during such year.''. (b) Ensuring Issuance of National Coverage Determination During Transition Period.--Section 1862(l)(2) of the Social Security Act (42 U.S.C. 1395y(l)(2)) is amended by adding at the end the following new flush sentence: ``In the case of a request for a national coverage determination with respect to a breakthrough device (as defined in section 1861(nnn)), the Secretary shall ensure that a final decision is made on such request prior to the end of the transitional coverage period (as so defined) for such device if such request was submitted to the Secretary before the date that is 9 months (or 12 months, in the case such request is a request to which subparagraph (B) applies) before the last day of such period.''. (c) Funding.--In addition to amounts otherwise available, there are appropriated to the Centers for Medicare & Medicaid Services Program Management Account, out of any monies in the Treasury not otherwise appropriated, $10,000,000 for each of fiscal years 2025 through 2030, to remain available until expended, to carry out the amendments made by this section. I. SUMMARY AND BACKGROUND A. Purpose and Summary The purpose of this bill is to provide expedited Medicare coverage of certain Food and Drug Administration (FDA) approved devices as part of the Breakthrough Devices Program. The bill would require the Centers for Medicare and Medicaid Services (CMS) to evaluate applications for a four-year transitional coverage period for certain medical devices approved as part of the Breakthrough Devices Program. B. Background and Need for Legislation In 2016, the 21st Century Cures Act created a new pathway for ``breakthrough'' medical devices to receive expedited FDA approval. According to the FDA website, the Breakthrough Devices Program is intended to ``provide patients and health care providers with timely access to medical devices by speeding up development, assessment, and review for premarket approval, 510(k) clearance, and De Novo marketing authorization. Breakthrough Devices must meet the FDA's rigorous standards for device safety and effectiveness in order to be authorized for marketing.'' The criteria to be eligible for the Breakthrough Devices Program is the device must first provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human disease or conditions and second meet one of the following criteria--represent breakthrough technology, have no approved or cleared alternative, offer a significant advantage over existing approved or cleared alternatives, or the availability of the device is in the best interest of patients. Unfortunately, at the time Congress passed the 21st Century Cures Act, Congress did not create a corresponding pathway for coverage at CMS. This means the 95 devices that have received approval under the Breakthrough Devices Program as of December 31, 2023 were not assured of coverage under the Medicare program--denying seniors access to materially better treatments. According to the Stanford Byers Center for Biodesign, it takes Medicare over five years on average to provide coverage for a breakthrough device. The lack of companion Medicare coverage pathway for Breakthrough Devices is needlessly denying seniors access to innovative medical treatments. It is essential for Congress to provide a pathway for transitional coverage for these devices within Medicare. C. Legislative History

Background

H.R. 1691 was introduced on March 22, 2023, and was referred to the Committee on Ways and Means and the Committee on Energy and Commerce. Committee Hearings The Committee on Ways and Means held the following hearing concerning the policy in H.R. 1691: On May 10, 2023, the Committee on Ways and Means Health Subcommittee held a hearing titled, ``Examining Policies that Inhibit Innovation and Patient Access'' to probe policies limiting the number of innovative treatments and cures that reach patients. The hearing explored the limited coverage of breakthrough medical devices, previous administrative efforts to fix the problem, and how Congressional intervention is necessary to lessen the gap between FDA approval and CMS coverage.

Committee Action

The Committee on Ways and Means marked up H.R. 1691, the Ensuring Patient Access to Critical Breakthrough Products Act, on June 27, 2024, and favorably reported the bill, as amended, to the House of Representatives (with quorum being present). D. Designated Hearing Pursuant to clause 3(c)(6) of rule XIII, the following hearing was used to develop and consider H.R. 1691: ``Examining Policies that Inhibit Innovation and Patient Access'' on May 10, 2023. II. EXPLANATION OF THE BILL A. Reasons for Change The Committee on Ways and Means' reason for change is to solve the underlying problem of long waits between FDA approval of Breakthrough Devices and their coverage under Medicare. B. Explanation of Provisions Section 1. Short title. The short title is ``Ensuring Patient Access to Critical Breakthrough Products Act of 2024''. Section 2. Ensuring Prompt Coverage of Breakthrough Devices Under the Medicare Program. This provision provides a distinct pathway for four years of transitional Medicare coverage of certain FDA approved breakthrough medical devices and requires the Centers for Medicare and Medicaid Services (CMS) to make a permanent coverage determination by the end of the coverage period if so requested. C. Effective Date The bill would become effective 18 months after the date of enactment. III. VOTES OF THE COMMITTEE In compliance with the Rules of the House of Representatives, the following statement is made concerning the vote of the Committee on Ways and Means during the markup consideration of H.R. 1691, the ``Ensuring Patient Access to Critical Breakthrough Products Act of 2023,'' on June 27, 2024. H.R. 1691 was ordered favorably reported to the House of Representatives as amended by a roll call vote of 36 yeas to 5 nays (with a quorum being present). The vote was as follows: ---------------------------------------------------------------------------------------------------------------- Representative Yea Nay Present Representative Yea Nay Present ---------------------------------------------------------------------------------------------------------------- Mr. Smith (MO)..................... X ...... ......... Mr. Neal............. ...... X ......... Mr. Buchanan....................... X ...... ......... Mr. Doggett.......... ...... X ......... Mr. Smith (NE)..................... X ...... ......... Mr. Thompson......... X ...... ......... Mr. Kelly.......................... X ...... ......... Mr. Larson........... ...... X ......... Mr. Schweikert..................... X ...... ......... Mr. Blumenauer....... X ...... ......... Mr. LaHood......................... X ...... ......... Mr. Pascrell......... ...... X ......... Dr. Wenstrup....................... X ...... ......... Mr. Davis............ X ...... ......... Mr. Arrington...................... X ...... ......... Ms. Sanchez.......... X ...... ......... Dr. Ferguson....................... X ...... ......... Ms. Sewell........... X ...... ......... Mr. Estes.......................... X ...... ......... Ms. DelBene.......... X ...... ......... Mr. Smucker........................ X ...... ......... Ms. Chu.............. ...... X ......... Mr. Hern........................... X ...... ......... Ms. Moore............ X ...... ......... Ms. Miller......................... X ...... ......... Mr. Kildee........... X ...... ......... Dr. Murphy......................... ...... ...... ......... Mr. Beyer............ X ...... ......... Mr. Kustoff........................ X ...... ......... Mr. Evans............ ...... ...... ......... Mr. Fitzpatrick.................... X ...... ......... Mr. Schneider........ X ...... ......... Mr. Steube......................... X ...... ......... Mr. Panetta.......... X ...... ......... Ms. Tenney......................... X ...... ......... Mr. Gomez............ X ...... ......... Mrs. Fischbach..................... X ...... ......... Mr. Moore.......................... X ...... ......... Mrs. Steel......................... X ...... ......... Ms. Van Duyne...................... X ...... ......... Mr. Feenstra....................... X ...... ......... Ms. Malliotakis.................... X ...... ......... Mr. Carey.......................... X ...... ......... ---------------------------------------------------------------------------------------------------------------- IV. BUDGET EFFECTS OF THE BILL A. Committee Estimate of Budgetary Effects With respect to clause 3(d) of rule XIII of the Rules of the House of Representatives, the following statement is made concerning the effects on the budget of the bill, H.R. 1691, as reported. The estimate prepared by the Congressional Budget Office is included below. B. Statement Regarding New Budget Authority and Tax Expenditures Budget Authority In compliance with clause 3(c)(2) of rule XIII of the Rules of the House of Representatives, the Committee states that the bill involved no new or increased budget authority. The Committee states further that the bill involves no new or increased tax expenditures. C. Cost Estimate Prepared by the Congressional Budget Office In compliance with clause 3(c)(3) of rule XIII of the Rules of the House of Representatives, requiring a cost estimate prepared by the CBO, the following statement by CBO is provided. The bill would: Require Medicare to automatically cover certain medical devices for a four-year period following approval from the Food and Drug Administration (FDA) Estimated budgetary effects would mainly stem from: Increases in new technology add-on payments (NTAPs) to hospitals for medical devices that would not otherwise have been covered by Medicare The shorter period between FDA approval of a device and NTAPs made to hospitals Increases in payments to Medicare Advantage plans Areas of significant uncertainty include: The number and cost of medical devices likely to be approved by the FDA and eligible for automatic coverage Bill summary: H.R. 1691 would require Medicare to automatically cover devices approved under the Breakthrough Devices Program of the Food and Drug Administration (FDA). That program is directed at simplifying the approval process for devices used in the treatment of especially severe diseases and conditions. Under the bill, Medicare would be required to cover devices within four years of FDA approval. Estimated Federal cost: The estimated budgetary effect of H.R. 1691 is shown in Table 1. The costs of the legislation fall within budget function 570 (Medicare). TABLE 1.--ESTIMATED BUDGETARY EFFECTS OF H.R. 1691 -------------------------------------------------------------------------------------------------------------------------------------------------------- By fiscal year, millions of dollars-- ----------------------------------------------------------------------------------------------------- 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2025-2029 2025-2034 -------------------------------------------------------------------------------------------------------------------------------------------------------- INCREASES OR DECREASES (-) IN DIRECT SPENDING Estimated Budget Authority........................ 10 10 38 84 99 118 125 144 175 191 241 994 Estimated Outlays................................. 5 8 38 84 99 118 131 145 175 191 234 994 -------------------------------------------------------------------------------------------------------------------------------------------------------- Basis of estimate: For this estimate, CBO assumes that H.R. 1691 will be enacted early in fiscal year 2025. The Medicare program does not automatically cover the use of every medical device approved by the FDA; Medicare conducts its own evaluations--reviews that can delay or prevent payments to hospitals that use the devices in treating beneficiaries. CBO expects that enacting H.R. 1691 would lead Medicare to cover more FDA-approved breakthrough devices and that the program's payments to hospitals would increase as a result. In particular, spending would rise for new technology add-on payments (NTAPs), which supplement Medicare's payments to hospitals for treatments that have been identified as novel, effective, and costly. CBO estimates that under current law, over the 2027-2034 period, NTAPs will amount to $1.6 billion for roughly 120 breakthrough devices, at a cost of about $13 million per device. (Because devices typically can qualify for NTAPs for multiple years, the annual payment per device will be less than $13 million.) Direct spending: Based on analyses of the rate and timing of NTAPs for breakthrough devices, CBO expects that enacting H.R. 1691 would increase by roughly 25 percent the number of devices that would be covered by Medicare and eligible for NTAPs. As a result, over the 2025-2034 period, fee-for-service spending would increase by about $409 million for Medicare and by $525 million for Medicare Advantage plans. H.R. 1691 also would appropriate $10 million each year between 2025 and 2030 to cover the administrative costs of implementing the bill. Based on the cost of similar activities, CBO estimates the appropriations would cost $60 million over the 2025-2034 period. In total, CBO estimates that enacting H.R. 1691 would increase direct spending by $994 million over the 2025-2034 period (see Table 1). Uncertainty: CBO's estimate for H.R. 1691 is subject to considerable uncertainty. The FDA's pace of device approvals has accelerated in the recent past. According to data from the agency, more than twice as many devices were approved between 2021 and 2023 than were approved between 2018 and 2020.\1\ Although this estimate is based on the number of currently approved breakthrough devices, it is difficult to predict how many FDA will approve over the next few years or what Medicare would spend on their coverage. --------------------------------------------------------------------------- \1\Food and Drug Administration, ``Breakthrough Devices Program'' (March 2024), https://tinyurl.com/55zyyvs8. --------------------------------------------------------------------------- Pay-As-You-Go considerations: The Statutory Pay-As-You-Go Act of 2010 establishes budget-reporting and enforcement procedures for legislation affecting direct spending or revenues. The net changes in outlays that are subject to those pay-as-you-go procedures are shown in Table 1. Increase in long-term net direct spending and deficits: CBO estimates that enacting H.R. 1691 would increase net direct spending by more than $2.5 billion in any of the four consecutive 10-year periods beginning in 2035. CBO estimates that enacting H.R. 1691 would increase on- budget deficits by more than $5 billion in any of the four consecutive 10-year periods beginning in 2035. Mandates: The bill contains no intergovernmental or private-sector mandates as defined in the Unfunded Mandates Reform Act. Estimate prepared by: Federal costs: Sarah Sajewski; Mandates: Brandon Lever. Estimate reviewed by: Asha Saavoss, Chief, Health Systems and Medicare Cost Estimates Unit; Kathleen FitzGerald, Chief, Public and Private Mandates Unit; Chad Chirico, Director of Budget Analysis. Estimate approved by: Phillip L. Swagel, Director, Congressional Budget Office. V. OTHER MATTERS TO BE DISCUSSED UNDER THE RULES OF THE HOUSE A. Committee Oversight Findings and Recommendations With respect to clause 3(c)(1) of rule XIII of the Rules of the House of Representatives, the Committee made findings and recommendations that are reflected in this report. B. Statement of General Performance Goals and Objectives With respect to clause 3(c)(4) of rule XIII of the Rules of the House of Representatives, the Committee advises that the bill does not authority funding, so no statement of general performance goals and objectives is required. C. Information Relating to Unfunded Mandates This information is provided in accordance with section 423 of the Unfunded Mandates Reform Act of 1995 (Pub. L. No. 104- 4). The Committee has determined that the bill does not contain Federal mandates on the private sector. The Committee has determined that the bill does not impose a Federal intergovernmental mandate on State, local, or tribal governments. D. Congressional Earmarks, Limited Tax Benefits, and Limited Tariff Benefits With respect to clause 9 of rule XXI of the Rules of the House of Representatives, the Committee has carefully reviewed the provisions of the bill, and states that the provisions of the bill do not contain any congressional earmarks, limited tax benefits, or limited tariff benefits within the meaning of the rule. E. Duplication of Federal Programs In compliance with clause 3(c)(5) of rule XIII of the Rules of the House of Representatives, the Committee states that no provision of the bill establishes or reauthorizes: (1) a program of the Federal Government known to be duplicative of another Federal program; (2) a program included in any report from the Government Accountability Office to Congress pursuant to section 21 of Public Law 111-139; or (3) a program related to a program identified in the most recent Catalog of Federal Domestic Assistance, published pursuant to the Federal Program Information Act (Pub. L. No. 95-220, as amended by Pub. L. No. 98-169). VI. CHANGES IN EXISTING LAW MADE BY THE BILL, AS REPORTED In compliance with clause 3(e) of rule XIII of the Rules of the House of Representatives, changes in existing law made by the bill, as reported, are shown as follows. Changes in Existing Law Made by the Bill, as Reported In compliance with clause 3(e) of rule XIII of the Rules of the House of Representatives, changes in existing law made by the bill, as reported, are shown as follows (existing law proposed to be omitted is enclosed in black brackets, new matter is printed in italics, and existing law in which no change is proposed is shown in roman): SOCIAL SECURITY ACT * * * * * * * TITLE XVIII--HEALTH INSURANCE FOR THE AGED AND DISABLED * * * * * * * Part E--Miscellaneous Provisions definitions of services, institutions, etc. Sec. 1861. For purposes of this title-- Spell of Illness (a) The term ``spell of illness'' with respect to any individual means a period of consecutive days-- (1) beginning with the first day (not included in a previous spell of illness) (A) on which such individual is furnished inpatient hospital services, inpatient critical access hospital services or extended care services, and (B) which occurs in a month for which he is entitled to benefits under part A, and (2) ending with the close of the first period of 60 consecutive days thereafter on each of which he is neither an inpatient of a hospital or critical access hospital nor an inpatient of a facility described in section 1819(a)(1) or subsection (y)(1). Inpatient Hospital Services (b) The term ``inpatient hospital services'' means the following items and services furnished to an inpatient of a hospital and (except as provided in paragraph (3)) by the hospital-- (1) bed and board; (2) such nursing services and other related services, such use of hospital facilities, and such medical social services as are ordinarily furnished by the hospital for the care and treatment of inpatients, and such drugs, biologicals, supplies, appliances, and equipment, for use in the hospital, as are ordinarily furnished by such hospital for the care and treatment of inpatients; and (3) such other diagnostic or therapeutic items or services, furnished by the hospital or by others under arrangements with them made by the hospital, as are ordinarily furnished to inpatients either by such hospital or by others under such arrangements; excluding, however-- (4) medical or surgical services provided by a physician, resident, or intern, services described by subsection (s)(2)(K), certified nurse-midwife services, qualified psychologist services, and services of a certified registered nurse anesthetist; and (5) the services of a private-duty nurse or other private-duty attendant. Paragraph (4) shall not apply to services provided in a hospital by-- (6) an intern or a resident-in-training under a teaching program approved by the Council on Medical Education of the American Medical Association or, in the case of an osteopathic hospital, approved by the Committee on Hospitals of the Bureau of Professional Education of the American Osteopathic Association, or, in the case of services in a hospital or osteopathic hospital by an intern or resident-in-training in the field of dentistry, approved by the Council on Dental Education of the American Dental Association, or in the case of services in a hospital or osteopathic hospital by an intern or resident-in-training in the field of podiatry, approved by the Council on Podiatric Medical Education of the American Podiatric Medical Association; or (7) a physician where the hospital has a teaching program approved as specified in paragraph (6), if (A) the hospital elects to receive any payment due under this title for reasonable costs of such services, and (B) all physicians in such hospital agree not to bill charges for professional services rendered in such hospital to individuals covered under the insurance program established by this title. Inpatient Psychiatric Hospital Services (c) The term ``inpatient psychiatric hospital services'' means inpatient hospital services furnished to an inpatient of a psychiatric hospital. Supplier (d) The term ``supplier&#x27

Dissenting Views

There are more than 67 million Americans on Medicare, and they deserve timely access to medical innovations that can meaningfully improve and extend their lives. But right now, patients face multi-year delays even after these breakthrough devices are deemed safe and effective by the FDA. According to the Stanford University Byers Center for Bio-design, it takes a median time of over 5 years after the FDA approves or clears these devices for Medicare to cover them. These delays can have profound consequences for patients. For example, a novel medical device called Optune received FDA approval in 2011 to treat glioblastoma, one of the most deadly and difficult to treat brain cancers that more than 10,000 Americans are diagnosed with every year. Medicare did not cover this treatment until 2019--eight years after being deemed safe and effective by the FDA and years after all major private health plans covered it. That same study from Stanford found that the only statistically significant factor in predicting how long CMS takes to approve a novel device is not the strength of the clinical evidence, but the size of the company that manufactures the device. So, if a company has more money and manpower to devote to this bureaucratic coverage process, they tend to get their products covered faster. This harms smaller innovators while seniors pay the price. If you or your loved one is on Medicare, you should not be forced to use less effective treatments, or experience delays in lifesaving care, because Medicare is dragging its feet on covering a more effective FDA-approved product. We can do better. That's why I introduced bipartisan legislation with Reps. Wenstrup, Sewell, Moore, Cardenas, and Bilirakis, as well as Energy and Commerce Health Subcommittee Chairman Guthrie and Ranking Member Eshoo, to speed up coverage and increase access for seniors. The breakthrough designation was first created by Congress in 2015 under the bipartisan 21st Century Cures Act to speed up FDA review. Versions of our bill to speed up Medicare review have been introduced since 2016 when it was first sponsored by Rep. Boustany and Ranking Member Neal. I thank the Ranking Member, Chairman, and their staffs for continuing to improve this bill, which now has 86 bipartisan cosponsors and was marked up with strong support in the Energy & Commerce Committee last November. Here are just some of the improvements made to the bill: First, by tightening the criteria for what breakthrough devices are eligible, we have reduced the estimated cost of this legislation by more than 75 percent. Second, the bill has strong safety standards, requires all devices to be deemed safe and effective by FDA, and empowers CMS with the ability to block coverage if there are potential other harms. Third, the bill requires all devices to provide sufficient clinical trial data that includes patients from the Medicare population to confirm these products are safe and effective. And fourth, the bill provides $10 million per year for the next six years for CMS to build out this new program. I want to remind my colleagues: to receive a breakthrough designation by the FDA, a device must provide more effective treatment or diagnosis of life-threatening or debilitating diseases, have no approved alternatives, or offer significant advantages over existing options. These are not just any run- of-the-mill medical devices. These include novel devices that can significantly reduce bleeding complications during open heart surgeries, diagnose skin cancer in real time, ease tremors and stiffness for patients with Parkinson's disease, and significantly decrease blood sugar levels. Through 2023, out of the 933 devices that have received breakthrough designation by the FDA over the past decade, fewer than 100 have actually been approved by the FDA. So, we are talking about a very limited group of groundbreaking devices that can really improve the lives of seniors in Washington state and across the country. And let's also keep in mind that Medicare does eventually cover these devices. It just takes many years. And while seniors wait, they are forced to pay exorbitant out of pocket costs for these life-saving devices or are denied access to them altogether. Let's think about that for a second. I urge my colleagues to vote yes on this important legislation. Suzan K. DelBene. [all]

Source: https://api.congress.gov/v3/committee-report/118/hrpt/952